News

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.
Eli Lilly plans to manufacture its new weight-loss pill in the US for patients around the world as Trump presses companies to ...
Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...
A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its ...
Eli Lilly said its phase 3 trial of GLP-1 drug in pill form found results similar to popular injectables for weight loss. Orforglipron would be used as a daily pill, eliminating the need for ...
Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...
Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...
Key Takeways U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...